British CD­MO Ster­ling part­ners up on low-cost man­u­fac­tur­ing of mol­nupi­ravir

A British CD­MO and the Uni­ver­si­ty of Man­ches­ter have teamed up to sup­port the de­vel­op­ment of low-cost man­u­fac­tur­ing of mol­nupi­ravir, the an­tivi­ral pill for Covid-19 that an FDA ad­comm rec­om­mend­ed for an EUA ear­li­er this week.

Man­ches­ter’s In­sti­tute of Biotech­nol­o­gy en­list­ed Ster­ling to pro­vide chem­i­cal scale-up and process de­vel­op­ment ex­per­tise. That could po­ten­tial­ly pro­vide broad­er ac­cess of mol­nupi­ravir to low­er-in­come coun­tries. The school has re­ceived grant fund­ing from the Bill & Melin­da Gates Foun­da­tion for the project.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER